Research programme: HCV and HIV polymerase inhibitors - Roche

Drug Profile

Research programme: HCV and HIV polymerase inhibitors - Roche

Alternative Names: RO-0622; RO-9187

Latest Information Update: 06 May 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Class Deoxyribonucleosides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Hepatitis C; HIV-1 infections

Most Recent Events

  • 26 Apr 2009 Preclinical trials in HIV-1 infections in Europe (unspecified route)
  • 26 Apr 2009 Antimicrobial data from a preclinical study presented at the 44th Annual Meeting of the European Association for the study of the Liver (EASL-2009)
  • 20 Feb 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top